A trans-splicing ribozyme which can specifically reprogram human telomerase reverse transcriptase (hTERT) RNA was previously suggested as a useful agent for tumor-targeted gene therapy. In this study, we evaluated in vivo function of the hTERT-targeting trans-splicing ribozymes by employing the molecular analysis of expression level of genes affected by the ribozyme delivery into peritoneal carcinomatosis mice model. To this effect, we constructed adenoviral vector encoding the specific ribozyme. Noticeably, more than four-fold reduction in the level of hTERT RNA was observed in tumor nodules by the systemic infection of the ribozyme-encoding virus. Such hTERT RNA knockdown in vivo induced changes in the global gene expression profile, including the suppression of specific genes associated with anti-apoptosis including bcl2, and genes for angiogenesis and metastasis. In addition, specific trans-splicing reaction with the targeted hTERT RNA took place in the tumors established as peritoneal carcinomatosis in mice by systemic delivery of the ribozyme. In conclusion, this study demonstrates that an hTERT-specific RNA replacement approach using trans-splicing ribozyme represents a potential modality to treat cancer.
Introduction
Telomerase is a multicomponent ribonucleoprotein located within the nucleus that synthesizes the repetitive nucleotide sequence forming the telomeres at the end of chromosomes (Morin, 1989) . Telomerase activity appears to stabilize telomeres and allow the possibility of cellular immortality (Zhu et al., 1999) . Of note, telomerase activity is highly activated in 80-90% of malignant tissues and immortal cell lines (Kim et al., 1994) and the activity is modulated mainly by the telomerase reverse transcriptase (TERT), the catalytic subunit of the telomerase. Therefore, TERT is a useful target for the development of anti-cancer agent.
The group I ribozyme from Tetrahymena thermophila was previously demonstrated to trans-splice an exon that is attached to its 3' end onto a separate 5' exon RNA, not only in vitro (Been and Cech, 1986) but also in E. coli (Sullenger and Cech, 1994) and mammalian cells (Jones et al., 1996) . We, as well as other groups, have shown that these group I-based trans-splicing ribozymes can revise mutant transcripts that are associated with several human genetic or malignant diseases (Lan et al., 1998; Phylactou et al., 1998; Watanabe and Sullenger, 2000; Rogers et al., 2002; Shin et al., 2004) . Moreover, we demonstrated that transsplicing ribozymes could selectively and specifically induce therapeutic gene activities in specific RNA-expressing cells through specific replacement of the target transcript (Ryu et al., 2003) . Accordingly, we developed human TERT (hTERT) RNAreplacing trans-splicing ribozyme that can stimulate the hTERT-dependent cytotoxicity in tumor cells (Kwon et al., 2005) . Furthermore, we recently showed that adenoviral vector harboring the ribozyme can either selectively mark tumor cells or selectively induce suicide gene activity in the tumors, thereby regressing the tumors with the Figure 1 . Scheme of ribozyme-mediated selective induction of new RNA coupled with reduction of target RNA by targeted trans-splicing of hTERT mRNA. A ribozyme can recognize hTERT RNA at accessible uridine residue by base pairing to the sequence through its internal guide sequence. The ribozyme then removes the sequence downstream of the target site and replaces it with a 3' exon that encodes a lacZ RNA sequence in this study.
prodrug treatment, in hTERT-expressing tumor xenografts (Hong et al., 2007) . These observations indicate that the trans-splicing ribozyme can be used as anti-cancer agents that reprogram cancerspecific transcripts to frustrate the cancerous cells.
The hTERT-specific trans-splicing ribozyme will be more effective as anti-cancer tool because it can induce therapeutic transgene activity selectively in the telomerase-positive cancer cells and can simultaneously reduce the hTERT RNA level in the cells (Figure 1 ). In this study, to evaluate the dual activity of the ribozyme and to analyze gene expression responses upon hTERT RNA reduction by the ribozyme in vivo, we observed any alterations of the gene expression profiles of tumor nodules in mice with intraperitoneal carcinomatosis after systemic delivery of the hTERT-targeting ribozyme.
Materials and Methods

Cell lines
The Hep3B cells (human hepatocellular carcinoma cell line) were purchased from the American Type Culture Collection. The cells were maintained in Eagle minimal essential medium, supplemented with 10% heat-inactivated FBS (Join Bio-Innovation, Seoul, Korea), 50 U/ml penicillin G, and 50 µg/ml streptomycin (Sigma, St. Louis, MO) at 37 o C in a humidified atmosphere of 5% CO2.
Generation of recombinant adenoviral vectors
We constructed hTERT-specific trans-splicing ribozyme under the control of a phosphoenolpyruvate carboxykinase (PEPCK) promoter as previously described (Song and Lee, 2006) . The expression of the specific ribozyme harboring diphtheria toxin A or HSVtk with the PEPCK promoter was shown to be the most effective and specific with regard to the retardation of the growth of hTERT + liver cancer cells, as compared with other liver-specific promoters (Song and Lee, 2006) . Recombinant adenovirus vector encoding the PEPCK promoterderived hTERT-targeting ribozyme flanked by the cDNA for LacZ (β-galactosidase) as 3' exon ( Figure 2A ) was constructed using the in vivo homologous recombination technique in bacteria (BJ5183) with a type 5 adenoviral vector backbone in which the E1 and E3 region have been deleted (pAdenoVator ∆E1/E3 backbone E1/E3 deleted Ad5 genome, AdenoVector TM , Qbiogene, Irvine, CA). Briefly, a SpeI/BstBI fragment containing the PEPCK promoter-Rib21AS-LacZ sequence was inserted into the pAdenoVator-CMV5-IRES-GFP shuttle vector. To construct recombinant virus vector, the shuttle plasmid was cleaved with PmeI. The linearized fragment was cotransformed into BJ5183 cells with AdenoVector TM . The recombinant vectors generated by homologous recombination in BJ5183 cells were isolated, analyzed with restriction enzymes, and linearized with PacI. The linearized vectors were then transfected into 293 cells and the produced recombinant adenoviruses were isolated by three rounds of plaque purification. Recombinant viruses were amplified using 293 cells, purified and concentrated by Vivapure 
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TM 100 (Sartorius AG, Edgewood, NY). Recombinant adenovirus was titered by determination of the TCID50 (tissue culture infectious dose for 50% of the cells). We designated the recombinant adenovirus encoding for the ribozyme with lacZ under the control of the PEPCK promoter as Ad-PEPCK.Ribo-LacZ. An adenovirus with lacZ driven by the PEPCK promoter (Ad-PEPCK-LacZ) was employed as a control. Viral stocks were stored in 10% sucrose and kept at 80 o C until use.
Molecular analysis of recombinant virus
Recombinant viral vector generated by homologous recombination in BJ5183 cells was confirmed by digestion with NotI. For the analysis of recombinant viral genomic DNA, viral supernatant generated in 293 cells were isolated, and the presence of lacZ and ITR gene was assessed using PCR. Viral supernatant from plaque isolation was infected into Hep3B. Total RNA was then isolated from the cell line and reverse transcribed with an oligo(dT) primer in the presence of 10 mM Largininamide to confirm the promoter activity of the recombinant virus. The cDNAs were amplified with lacZ primer (5'-GGAATTCTGGTCGTTTTACAAC-GTCGTG-3' and 5'-GGGAAGCTTCGGATTGACC-GTAATGGGA-3'), or human GAPDH primer (5'-TGACATCAAGAAGGTGGTGA-3' and 5'-TGCAC-GACCCTGTTGCTG-3') as internal control. Infected cells were also used to measure β-galactosidase activity through incubation of cell extracts in 37 o C for 2 h with O-nitrophenyl β-D-galactopyranoside (Sigma, St. Louis, MO) as a substrate.
Animals
Four-to 5-week-old male BALB/cAnNCrI nude mice (Orient Bio Inc., Seongnam, Korea) were used throughout this study. The animals were kept under specific pathogen-free (SPF) conditions and acclimated to laboratory conditions for at least 1 wk before use and maintained in Korean FDA animal facility in accordance with AAALAC International Animal Care policy (Accredited Unit-Korea Food and Drug Administration : Unit number-000996).
Intraperitoneal carcinomatosis animal model
For the peritoneal carcinomatosis model of Hep3B liver cancer cells, 2 × 10 7 Hep3B cells were intraperitoneally injected into BALB/c male nude mice. In the pilot investigation, the animals showed peritoneal carcinomatosis within 21 days, easily detectable with gross inspection and a binocular stereomicroscope. To analyze specific transgene induction, we injected 1 × 10 9 pfu Ad-PEPCK-LacZ or Ad-PEPCK.Ribo-LacZ in PBS (total volume, 100 µl) intraperitoneally three times with two day interval after the carcinomatosis establishment. Two days after the last virus injection, the established tumor tissues were removed.
RNA analysis
Following tumor dissection, total RNA was extracted using Tri-Reagent according to the manufacturer's protocol (Molecular Research Center Inc., Cincinnati, OH). After re-suspension in nuclease-free water, the RNA was quantified by UV spectroscopy (Bio-Rad, Hercules, CA), and qualified on a 2100 Bioanalyzer (Agilent, Palo Alto, CA).
To assess the reduction level of the hTERT RNA in vivo by the ribozyme, hTERT cDNA was amplified using real time PCR from 2 µg total RNA of the hepatocarcinoma in mice two days after final adenovirus infection into intraperitoneal carcinomatosis mice model. Sequences of primers for the hTERT amplification are 5'-CGGAAGAGTGTCTG-GAGCAA-3' and 5'-GGATGAAGCGGAGTCTGGA-3'. All reagents except Taq polymerase (Takara, Otsu, Shiga, Japan) were obtained from the SYBRGreen core reagent kit (Molecular Probes, Eugene, OR). The protocol was followed as the manual of the PCR-kit [12.5 µl SYBR Green Mix, 0.2 µl cDNA, 1 µl primer pair mix (5 pmol/µl each primer), and 11.3 µl H 2 O] (Oh et al., 2006) . The conditions for the PCR are at 95 o C for 30 s, at 55 o C for 40 s, and at 72 o C for 1 min for 40 cycles. The relative kinetic method was applied using a standard curve constructed with 8-fold serial dilutions of hTERT gene obtained from the MCF7 breast cell line which was known to strongly express the hTERT gene (Villa et al., 1998) . The standard curve used for PCR is composed of 2 points (equivalent to 1 and 0.125 ng of hTERT PCR product). To control for the expression level of hTERT in the reaction mix, we used human GAPDH. The threshold levels obtained from the hTERT were adjusted to the threshold levels found in the GAPDH reaction to correct for minor variation in cDNA loading. For amplification, we used the Roter-Gene, a real time PCR machine (Corbett Life science, San Francisco, CA). To calculate relative quantification values, a threshold cycle (Ct), at which a statistically significant increase in fluorescence occurs, was derived from the resulting PCR profiles of each sample. Ct is a measure of the amount of template present in the starting reaction. To correct for different amounts of total cDNA in the starting reaction, Ct values for an endogenous control (GAPDH) were subtracted from those of the corresponding hTERT level, resulting in ∆Ct. The relative quantification value of hTERT RNA level is expressed as 2 -∆Ct giving the relative difference of the ribozyme virus-treated sample compared to the control virus-infected sample.
Level of bcl2 RNA and ribozyme RNA (LacZ) in the adenoviral injected tumor tissues were detected using RT-PCR of total RNA (Du et al., 2006) . Primers for the amplification are as follows: bcl2, 5'-CGGAATTCATTGTGGCTGCACTTGCT-3' and 5'-CCCAAGCTTCTGTTGCCCAACTGCAA-3'; LacZ, 5'-GGAATTCATGGTCGTTTTACAACGTCG-TG-3' and 5'-GGGAAGCTTCGGATTGACCGTAA-TGGGA-3'. Production of trans-spliced molecules (TS) with targeted hTERT and the possibility of TS generation with bcl2 RNA were assessed from the viral infected tumors. Total RNA was amplified with primers for TS with the hTERT RNA (5'-GGGGA-ATTCAGCGCTGCGTCCTGCT-3' and 5'-ATGGTC-GTTTTACAACGTCGTGAC-3') or with primers for TS with the bcl2 RNA (5'-CGGAATTCATGTTGT-TGGCCGGATCA-3' and 5'-ATGGTCGTTTTACAA-CGTCGTGAC-3').
Microarray analysis
We amplified and labeled total RNA from the hepatocarcinoma in mice infected with Ad-PEPCKLacZ or Ad-PEPCK.Ribo-LacZ with Cy3-dCTP or Cy5-dCTP (Perkin Elmer, Boston, MA), respectively. RNA labeling was employed using the Agilent Low Input Linear Amplification kit according to the manufacturer's protocols. Each of Cy3 and Cy5 labeled cDNA (0.8 -1 µg) was combined and hybridized to 60-mer oligonucleotides microarray with sequences representing 41,194 human genes (Agilent, chip No. HWG251239143090). The slides were hybridized with GlassHyb buffer using the Lucidea SlidePro automated hybridization instrument (Amersham Biosciences, Piscataway, NJ) with the protocol for Agilent slide. The dried slides were then scanned with the GenePix 4000B Microarray Scanner, and the initial images captured by the GenePix Pro 4.1 software (Axon Instruments, Union City, CA). The data were analyzed using Acuity software Version 3.1 (Axon Instruments).
Results
Construction of recombinant adenovirus
Expression vector for the hTERT-targeting ribozyme was constructed through the incorporation of a PEPCK.Ribo-LacZ sequence into a type 5 adenoviral vector backbone (Figure 2A ). The resulting plasmid is then linearized and co-transformed into E.coli strain BJ5183 with adenovirus backbone DNA in which the E1 and E3 region have been deleted. Recombinant viral vectors resulting from homologous recombination are selected with kanamycin and screened by restriction enzyme analysis. A restriction digest with NotI gives a restriction pattern as shown in Figure 2B (8 bands with size of 21829, 5571, 4999, 2589, 1931, 1886, 960 and 326 bp) . The recombinants were digested with PacI and transfected into 293 cells, where the E1 functions can be complemented, by calcium phosphate transfection method to allow production of recombinant adenoviral DNA and packaging into virions. Viral plaques generated in 293 cells were isolated and expanded. After 5 rounds of plaque purification, the expression cassette in the adenoviral vectors was confirmed by PCR of viral genomic DNA and lacZ gene using specific primer ( Figure 2C ).
Recombinant viruses were amplified using 293 cells, purified and concentrated, and β-galactosidase assay were performed to examine the expression of the lacZ 48 h after infection with either clone number 24 or 26 of recombinant virus into hTERT + Hep3B cells. As shown in Figure 2D and E, expression of lacZ was detected not only at RNA level but also at protein level in the adenoviral vector-infected Hep3B cells. In contrast, no β-galactosidase was observed in hTERT SK-LU-1 cells infected with the virus (data not shown). These results demonstrate that the recombinant viral vectors successfully and selectively induce the expression of transgene, lacZ, in liver cancer cells.
Microarray analysis of TERT-dependent gene expression
To determine which transcripts are affected in vivo by the hTERT-targeting trans-splicing ribozyme and to assess the specificity of the ribozyme, we first established animal model with peritoneal carcinomatosis by intraperitoneal transplantation of Hep3B cells into nude mice. Then, we systemically infected adenoviral vector encoding the ribozyme into the mice, and studied the gene expression profile using oligonucleotide microarray experiments in the tumor nodules established in the mice. Changes in the mRNA levels of tumor nodules were analyzed by comparing tumors injected with virus encoding the hTERT-targeting ribozyme (Ad-PEPCK.Ribo-LacZ, PRL) with those that were infected with control virus (Ad-PEPCKLacZ, PL). Caspase 9, apoptosis-related APAF3, APAF-3, Apoptotic protease-activating 1.705↑ cysteine peptidase factor 3, Apoptotic protease Mch-6, CASP-9, CASPASE-9c, Caspase-9 precursor, ICE-LAP6, ICE-like apoptotic protease 6, MCH6
*A subset of genes involved in apoptosis, angiogenesis and tumor metastasis, expression of which was increased (↑) or decreased (↓) more than 2-fold by treatment of Ad-PEPCK.Ribo-LacZ when compared with inoculation of the control adenovirus (Ad-PEPCK-LacZ), are shown. In accordance with the real-time PCR data in Figure 3D , level of hTERT mRNA was decreased 6.85 fold by the specific ribozyme. Only two days after systemic delivery of the PRL into the intraperitoneal carcinomatosis mice, we observed a ≥2-fold change of RNA level in 1,189 genes including hTERT gene out of surveyed 41,194 human genes in the established human hepatocellular carcinoma (HCC). Some of genes whose expression was changed by PRL are involved in apoptosis or tumorigenesis pathway, as shown in the microarray data with siRNA treatment against hTERT or RNA subunit of telomerase, hTER (Li et al., 2005; Shammas et al., 2005) ( Table 1) . Expression of genes involved in the process of anti-apoptosis was efficiently downregulated by PRL. Specific genes that have been found to play important roles in angiogenesis or metastasis were also down-regulated. Some of genes which were up-regulated were participated in apoptosis induction process. In contrast, no significant alteration in the expression level of genes involved in immune response including cytokines, interferons, or interferon-stimulated genes was observed by PRL injection, suggesting that ribozyme expression via PRL treatment of mice did not induce dsRNA-mediated nonspecific interferon response in the established HCC.
Effects on hTERT RNA level by Ad-PEPCK.Ribo-LacZ
To verify the results obtained from the microarray experiments, we assessed RNA level of hTERT genes by real time quantitative PCR using the SYBR Green method ( Figure 3A ). Expression level of the housekeeping gene, GAPDH, showed only minor difference between PL-or PRL-infected tumor groups and served as both a control for RT-PCR performance and a reference for relative quantification ( Figure 3B ). The analytical sensitivity of the real-time RT-PCR was determined with a series of dilutions of RT-PCR product (1 and 0.125 ng) of hTERT RNA. Amplification of the hTERT RNA transcripts at different concentrations showed linearity, and R 2 was 0.99 ( Figure 3C ). The threshold cycle number (Ct) of PCR of the hTERT RNA in tumors infected with PRL (Ct = 15.1) was higher than that with PL (Ct = 12.8) ( Figure D) . These results strongly suggest that the level of hTERT RNA was more than 4 fold reduced in tumors by the adenovirus encoding the hTERTspecific ribozyme, compared with the control virus. 
Analysis of gene expression affected by Ad-PEPCK.Ribo-LacZ
Using RT-PCR analysis, we confirmed PRL-mediated downregulation of the bcl2 gene expression, which was found to decrease more than 8 fold from the microarrray analysis ( Figure 4A ). In contrast with generation of trans-splicing product with the targeted hTERT RNA by PRL, no transsplicing was created with bcl2 RNA, indicating that at least the reduction of bcl2 gene expression was not due to nonspecific trans-splicing reaction with the hTERT-targeting ribozyme ( Figure 4B ). Moreover, RACE RT-PCR and sequencing analysis revealed that all of the trans-splicing products generated in HCC of the PRL-injected mice were from reactions only with the targeted hTERT RNA, implying target specificity of the trans-splicing ribozyme in vivo (data not shown). Collectively with the microarray analysis, these results indicated that PEPCK promoter-driven trans-splicing ribozyme specifically replaced the hTERT RNA and efficiently reduced RNA level of the target in vivo, resulting in alteration in the global gene expression pattern indicative of novel response pathway such as induction of apoptosis and suppression of angiogenesis or metastasis.
Discussion
The aim of this study was to validate in vivo function of hTERT-targeting trans-splicing ribozymes with molecular analysis of affected gene expression. The hTERT-specific trans-splicing ribozyme will be more advantageous than other anti-cancer agents because the ribozyme could selectively induce targeted expression of the therapeutic gene product in hTERT + cancer cells and simultaneously decrease in the level of target hTERT transcript, hence reducing endogenous telomerase activity. To broadly screen for molecular effects by the hTERT-specific ribozyme, we performed oligonucleotide microarray analysis of peritoneal carcinomatosis infected with the ribozyme-encoding adenovirus using the Whole Human Genome Oligo Microarray Kit from agilent, which represent all known genes and transcripts in the human genome. As expected, the level of hTERT RNA in tumors was significantly reduced by systemic delivery of PRL encoding the specific ribozyme. Moreover, approximately 3% of the whole human genes were changed in their expression level in tumors infected with PRL, compared with tumors with PL. No significant difference in the β-galactosidase activity was observed between tumors infected with PL and PRL (data not shown). Thus, this alteration might not be due to LacZ expression induced by the ribozyme but due to the inhibition of the hTERT RNA level.
Gross changes were observed two days after the adenovirus infection in the expressional levels of various genes involved in apoptosis and tumorigenesis, which may in part explain other findings that human cancer cells have a rapid and defined growth inhibitory response to telomerase depletion, even without telomere shortening (Folini et al., 2003; Li et al., 2004 Li et al., , 2005 . It is remarkable that the vast majority of apoptosis regulators which were down-regulated in ribozyme-expressing tumor nodules are proapoptotic genes. At this point, it is difficult to draw conclusions how hTERT may interact within the apoptotic cascade. However, the result of this experiment indicated the kinds of dysregulated genes, and therefore, could further guide our research direction regarding TERT function. The apoptosis regulating function of hTERT will be complicated, as suggested by a recent study describing the role of telomerase on apoptosis through modulation of Bcl2 expression (Del Buffalo et al., 2005) . In this study, we observed in vivo molecular associations between the level of hTERT mRNA and bcl2 transcript, which resulted from systemic delivery of the hTERT-specific transsplicing ribozyme (Figure 5 ), in agreement with the observation by Del Bufalo et al. (2005) , who showed that the inhibition of telomerase expression induced mitochondrial apoptosis by targeted intervention in Bcl2 expression and function. hTERT overexpression was also shown to interfere at an early stage of cell death pathway involved in mitochondrial alterations (Massard et al., 2006) . Moreover, telomerase was recently demonstrated to not only stabilize telomeres but also activate the expression of proliferation enhanced genes (Smith et al., 2003) . Furthermore, nuclear-targeted hTERT showed enhanced antiapoptotic activity by inhibition of nuclear export of endogenous hTERT in human embryonic kidney cells (Haendeler et al., 2003) . These results together with our gene expression profile data suggest that hTERT may directly or indirectly modulates the expression of genes implicated in intrinsic apoptosis pathway controlled by bcl2.
In conclusion, this study points to in vivo function of the hTERT-specific trans-splicing ribozyme. The ribozyme efficiently reduced the hTERT RNA level, which in turn reduced gene expression involved in anti-apoptosis, angiogenesis and tumor metastasis. The observation of the relation of apoptosis, angiogenesis and tumor metastasis with the activity and/or expression level of telomerase will be positively influential to design telomerase-targeting agent as anti-cancer modality because the level of these pathways noticeably affects tumor growth. Moreover, at the same time with global change of gene expression, the hTERT-specific ribozyme induced target-dependent generation of trans-splicing RNA product in vivo. Therefore, present study proves potential usefulness of the RNA replacement strategy with hTERT-specific trans-splicing ribozyme as therapeutic approach to cancer.
